Introduction
“Disordered eating” refers to chaotic or abnormal eating patterns, including conditions such as anorexia nervosa, bulimia nervosa (BN), binge eating disorder (BED), avoidant/restrictive food intake disorder, and emotional eating. 1 Disordered eating patterns involve maladaptive relationships with food, body image, and self-perception, intertwined with mental health issues.2 –4 Addressing the cognitive distortions behind disordered eating, such as emotional regulation difficulties and avoidance, is crucial in promoting intuitive eating—a more adaptive and healthy approach to food.2 –5 Furthermore, creating a sense of safety and groundedness enables individuals to develop resilience, which plays a key role in overcoming eating disorders.6,7
Given the high prevalence of eating disorders, affecting approximately 1 million Canadians, and their associated mortality rates—the highest among mental illnesses (with estimates of 10%–15% mortality), innovative approaches to treatment are crucial. 1 Traditional therapies for disordered eating, particularly those addressing food restriction, such as group cognitive behavioral therapy (CBT), are common; however, there is growing interest in alternative modalities such as psychedelic-assisted therapy (PaT).8 –12 PaT, and more specifically, ketamine-assisted therapy (KaT), is increasingly being studied for its potential to treat various mental health conditions.2,11,13 Robison et al. 11 reported findings in a case series where patients experienced symptom reductions across both their eating disorders and comorbid mental health conditions following group-based KaT. Ragnhildstveit et al. 14 demonstrated that repeated ketamine infusions resulted in complete remission in a patient with BN, sustained at a one-year follow-up. This highlights the need for further exploration into combining these two therapeutic modalities.5,11,15
Currently, there is a lack of research examining the synergistic effects of specifically combining KaT and group therapy for disordered eating, despite KaT showing promise in treating a range of mental health challenges.13,14 Moreover, literature demonstrating the potential of psychedelics in a multimodal, team-based approach to building resilience and cognitive flexibility is limited.2,11,16 –18
Addressing trauma and comorbidity in eating disorders
Eating disorders are often associated with a history of trauma, abuse, and neglect, alongside comorbid conditions such as depression and anxiety.2,5,19 PaT offers a unique opportunity to address these underlying traumas while improving resilience and cognitive flexibility. Cognitive shifts from top-down, rigid thinking to bottom-up processing can lead to more adaptive responses to emotional discomfort, reducing the need for disordered eating behaviors.2,11,20
Research indicates that PaT can enhance resilience by increasing tolerance for difficult emotions, facilitating a shift from avoidance to acceptance and empowerment.3,11,16 By addressing both the psychological and physiological aspects of eating disorders, PaT can help individuals develop a more balanced approach to food and self-care.2,4
Potential adverse effects of KaT
Investigations into KaT have yielded ample safety data, and a recent review on the long-term effects of ketamine found that they are typically self-limited, mild, and transient.21 –26 Common and expected effects of ketamine include: a transient elevation in blood pressure (BP) and heart rate (HR), poor balance, dizziness, blurred vision, double vision, tunnel vision, slurred speech, nausea, anticipatory anxiety, agitation and confusion.21,26,27 Uncommon effects of ketamine include: vomiting, insomnia that night, headache, irritable bladder, loss of appetite and muscle tremors. In very rare cases of allergy to ketamine, laryngospasm is a possible adverse effect.21,26,27 With low-dose lytic dosing, expected effects include slightly altered visual perception lasting approximately 15 min, relaxation and transient elevation in BP and HR; uncommon effects include mild transient nausea lasting approximately 10 min.21,26,27
Available data suggest that KaT-related hypertension is expected and not concerning when treating normotensive or well-controlled hypertension patients.28,29 Moreover, KaT-related hypertension tends to be in a similar range to BP elevations expected during exercise.29 –31 Existing data suggest stable or improving cognition levels with appropriate ketamine dosage. 26 Notably, a recent study of 448 KaT sessions reported an absence of major adverse effects, indicating low adverse effect frequency. 28 In addition, Tsang et al. 28 demonstrated that effective prevention of adverse effects such as nausea, vomiting, anxiousness, and hypertension can be achieved with prophylactic medications.
Group therapy for treatment of eating disorders
Research into group therapy for the treatment of eating disorders is showing promise, particularly in terms of CBT provided in a group setting.8 –10,12,15,32,33 O’Connor et al. 9 found that while there are limited high-quality studies that examine group psychotherapy for eating disorders, the evidence that is available is efficacious, particularly in the case of BED.
Understanding communities of practice
The idea of a community of practice (CoP) was originally defined by Lave and Wenger 34 as a like-minded community of individuals who choose to intentionally and consistently interact in a relational context to build a given skill set. 35 This concept was the foundational basis for the evidence-informed version of a CoP program used at roots to thrive (RTT) for the purpose of addressing mental health conditions that have been difficult to treat through first-line approaches. 35 Since 2019, the RTT program has operated within a defined CoP structure to deliver ketamine and psilocybin-assisted group therapy. 27 The CoP framework aims to foster resilience through the development of congruence 36 and a sense of coherence 37 alongside co-regulation, as informed by polyvagal theory. 38 CoP-based group therapy focuses on fostering somatic awareness and self-compassion to improve mental health outcomes, nervous system regulation, and resilience.11,27,35,39 Similarly, RTT’s CoP approach focuses on resilience development through four core practices: awareness development, regulation, connection through compassion, and alignment with purpose.28,35,39 Participants are thoroughly prepared and supported prior, during, and post all therapeutic sessions. 27
Implementing group PaT in a CoP setting
Given the efficacy of PaT in treating comorbid conditions and the complexity of eating disorder treatment, researchers are calling for more studies exploring PaT for eating disorders.5,40 –42 The addition of KaT to group therapy provides a window of increased neural plasticity, enabling individuals to process uncomfortable emotions and develop a healthier relationship with food. 11 Combining KaT with group therapy fosters resilience, self-compassion, and perspective shifts.11,35
Offering PaT within a CoP setting creates a safe environment where individuals can process their traumas and develop an intuitive relationship with food. This approach fosters a sense of belonging and shared healing, which is crucial for individuals with disordered eating patterns.2,3,35 CoPs provide a structure for integrating the insights gained through PaT, promoting long-term resilience and cognitive flexibility.27,35
Combining PaT with a CoP structure can facilitate significant personal transformation by providing a supportive relational space for processing emotions and developing healthier eating habits. PaT-induced cognitive shifts allow individuals to replace rigid thought patterns with more adaptive and flexible responses to their environment.2,11,16,27,35
In conclusion, combining PaT with group therapy, particularly within a CoP setting, presents a promising new direction for treating eating disorders. PaT has the potential to enhance cognitive flexibility, emotional resilience, and self-compassion, which are key factors in overcoming disordered eating patterns. Future research should continue to explore the synergistic effects of these therapeutic modalities, with a focus on addressing the underlying traumas and comorbid conditions that often accompany eating disorders.2,3,35
Acknowledgments
None.
Footnotes
ORCID iDs: Lara Jeletzky
https://orcid.org/0009-0000-6170-0578
Vivian W. L. Tsang
https://orcid.org/0000-0001-9401-008X
Contributor Information
Lara Jeletzky, Vancouver Island University, 900 Fifth St, Nanaimo, BC V9R 5S5, Canada.
Shannon Dames, Vancouver Island University, Nanaimo, BC, Canada.
Pamela Kryskow, University of British Columbia, Vancouver, BC, Canada.
Vivian W. L. Tsang, University of British Columbia, Vancouver, BC, Canada
Declarations
Ethics approval and consent to participate: Not applicable, this manuscript is a commentary, therefore not requiring ethics approval.
Consent for publication: All team members reviewed this submission and provided consent for its publication.
Author contributions: Lara Jeletzky: Conceptualization; Project administration; Resources; Writing – original draft; Writing – review & editing.
Shannon Dames: Conceptualization; Investigation; Project administration; Resources; Supervision; Visualization; Writing – review & editing.
Pamela Kryskow: Conceptualization; Resources; Supervision; Writing – review & editing.
Vivian W. L. Tsang: Conceptualization; Project administration; Resources; Supervision; Writing – review & editing.
Funding: The authors received no financial support for the research, authorship, and/or publication of this article.
Competing interests: The authors declare that there is no conflict of interest.
Availability of data and materials: Not applicable, this manuscript is a commentary and does not contain data, samples, or models.
References
- 1. Ponsonby R. National initiative for eating disorders [Internet]. Eating disorders in Canada, https://www.nied.ca/eating-disorders-in-canada (n.d., accessed 30 October 2024). [Google Scholar]
- 2. Calder A, Mock S, Friedli N, et al. Psychedelics in the treatment of eating disorders: rationale and potential mechanisms. Eur Neuropsychopharmacol 2023; 75: 1–14. [DOI] [PubMed] [Google Scholar]
- 3. MacNamara D. Nourished: connection, food, and caring for our kids (and everyone else we love). Vancouver, BC: Aona Books, 2023. [Google Scholar]
- 4. Roth G. Women, food, and God: an unexpected path to almost everything. First Scribner trade paperback edition. New York: Scribner, 2011. [Google Scholar]
- 5. Psychedelic treatment of eating disorders [Internet]. (Robison R. Interview), https://www.youtube.com/watch?v=4eVr6_bkvKo (2023, accessed 2 November 2024).
- 6. Carhart-Harris RL, Friston KJ. REBUS and the anarchic brain: toward a unified model of the brain action of psychedelics. Pharmacol Rev 2019; 71(3): 316–344. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7. Villiger D, Trachsel M. With great power comes great vulnerability: an ethical analysis of psychedelics’ therapeutic mechanisms proposed by the REBUS hypothesis. J Med Ethics 2023; 49(12): 826–832. [DOI] [PubMed] [Google Scholar]
- 8. Grenon R, Schwartze D, Hammond N, et al. Group psychotherapy for eating disorders: a meta-analysis. Int J Eat Disord 2017; 50(9): 997–1013. [DOI] [PubMed] [Google Scholar]
- 9. O’Connor E, Garceau C, Polhill S, et al. Evidence-based group therapy for eating disorders. Group Dyn Theory Res Pract 2024; 28(3): 163–177. [Google Scholar]
- 10. Okamoto Y, Miyake Y, Nagasawa I, et al. A 10-year follow-up study of completers versus dropouts following treatment with an integrated cognitive-behavioral group therapy for eating disorders. J Eat Disord 2017; 5(1): 52. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11. Robison R, Lafrance A, Brendle M, et al. A case series of group-based ketamine-assisted psychotherapy for patients in residential treatment for eating disorders with comorbid depression and anxiety disorders. J Eat Disord 2022; 10(1): 65. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12. Ricca V, Castellini G, Mannucci E, et al. Comparison of individual and group cognitive behavioral therapy for binge eating disorder. a randomized, three-year follow-up study. Appetite 2010; 55(3): 656–665. [DOI] [PubMed] [Google Scholar]
- 13. Timek A, Daniels-Brady C, Ferrando S. Improvement in depressive symptoms in a patient with severe and enduring anorexia nervosa and comorbid major depressive disorder using psychotherapy-assisted IV ketamine: a case report. J Eat Disord 2024; 12(1): 79. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14. Ragnhildstveit A, Jackson LK, Cunningham S, et al. Case report: unexpected remission from extreme and enduring bulimia nervosa with repeated ketamine assisted psychotherapy. Front Psychiatry 2021; 12: 764112. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15. Harper-Giuffre H, MacKenzie KR. Group psychotherapy for eating disorders. Washington, DC: American Psychiatric Press eBooks, 1992. [Google Scholar]
- 16. Gukasyan N, Schreyer CC, Griffiths RR, et al. Psychedelic-assisted therapy for people with eating disorders. Curr Psychiatry Rep 2022; 24(12): 767–775. [DOI] [PubMed] [Google Scholar]
- 17. Ragnhildstveit A, Slayton M, Jackson LK, et al. Ketamine as a novel psychopharmacotherapy for eating disorders: evidence and future directions. Brain Sci 2022; 12(3): 382. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18. Spriggs MJ, Kettner H, Carhart-Harris RL. Positive effects of psychedelics on depression and wellbeing scores in individuals reporting an eating disorder. Eat Weight Disord - Stud Anorex Bulim Obes 2021; 26(4): 1265–1270. [DOI] [PubMed] [Google Scholar]
- 19. Brewerton TD. Eating disorders, trauma, and comorbidity: focus on PTSD. Eat Disord 2007; 15(4): 285–304. [DOI] [PubMed] [Google Scholar]
- 20. Neuhaus EC, Slavich GM. Behavioral psychedelics: integrating mind and behavior to improve health and resilience. Front Psychiatry 2022; 13: 821208. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21. Aan Het Rot M, Collins KA, Murrough JW, et al. Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol Psychiatry 2010; 67(2): 139–145. [DOI] [PubMed] [Google Scholar]
- 22. Dwyer JB, Landeros-Weisenberger A, Johnson JA, et al. Efficacy of intravenous ketamine in adolescent treatment-resistant depression: a randomized midazolam-controlled trial. Am J Psychiatry 2021; 178(4): 352–362. [DOI] [PubMed] [Google Scholar]
- 23. Marcantoni WS, Akoumba BS, Wassef M, et al. A systematic review and meta-analysis of the efficacy of intravenous ketamine infusion for treatment resistant depression: January 2009 – January 2019. J Affect Disord 2020; 277: 831–841. [DOI] [PubMed] [Google Scholar]
- 24. Salloum NC, Fava M, Freeman MP, et al. Efficacy of intravenous ketamine treatment in anxious versus nonanxious unipolar treatment-resistant depression. Depress Anxiety 2019; 36(3): 235–243. [DOI] [PubMed] [Google Scholar]
- 25. Vande Voort JL, Morgan RJ, Kung S, et al. Continuation phase intravenous ketamine in adults with treatment-resistant depression. J Affect Disord 2016; 206: 300–304. [DOI] [PubMed] [Google Scholar]
- 26. Nikayin S, Murphy E, Krystal JH, et al. Long-term safety of ketamine and esketamine in treatment of depression. Expert Opin Drug Saf 2022; 21(6): 777–787. [DOI] [PubMed] [Google Scholar]
- 27. Tsang VWL, Tao B, Dames S, et al. Safety and tolerability of intramuscular and sublingual ketamine for psychiatric treatment in the Roots to Thrive ketamine-assisted therapy program: a retrospective chart review. Ther Adv Psychopharmacol 2023; 13: 204512532311715. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28. Tsang VWL, Tao B, Dames S, et al. Safety and tolerability of intramuscular and sublingual ketamine for psychiatric treatment in the Roots to Thrive ketamine assisted therapy program. Eur Psychiatry 2023; 66(S1): S605–S606. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29. Zhou YL, Liu WJ, Wang CY, et al. Cardiovascular effects of repeated subanaesthetic ketamine infusion in depression. J Psychopharmacol 2021; 35(2): 159–167. [DOI] [PubMed] [Google Scholar]
- 30. Rowell LB. Blood pressure regulation during exercise. Ann Med 1991; 23(3): 329–333. [DOI] [PubMed] [Google Scholar]
- 31. Wielemborek-Musial K, Szmigielska K, Leszczynska J, et al. Blood pressure response to submaximal exercise test in adults. BioMed Res Int 2016; 2016: 1–8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32. Wade S, Byrne S, Allen K. Enhanced cognitive behavioral therapy for eating disorders adapted for a group setting. Int J Eat Disord 2017; 50(8): 863–872. [DOI] [PubMed] [Google Scholar]
- 33. Moore E, Waller G. Brief group cognitive-behavioral therapy for bulimia nervosa and binge-eating disorder: a pilot study of feasibility and acceptability. Int J Eat Disord 2023; 56(6): 1228–1232. [DOI] [PubMed] [Google Scholar]
- 34. Lave J, Wenger E. Situated learning: legitimate peripheral participation. Cambridge: Cambridge University Press, 1991. [Google Scholar]
- 35. Dames S, Kryskow P, Watler C. A cohort-based case report: the impact of ketamine-assisted therapy embedded in a community of practice framework for healthcare providers with PTSD and depression. Front Psychiatry 2022; 12: 803279. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36. Rogers C. A theory of therapy, personality and interpersonal relationships as developed in the client-centred framework. New York: McGraw Hill, 1959. [Google Scholar]
- 37. Antonovsky A. Health, stress, and coping. 1st ed. San Francisco: Jossey-Bass Publishers, 1980, p. 255. (The Jossey-Bass social and behavioral science series). [Google Scholar]
- 38. Porges S. The polyvagal theory: neurophysiological foundations of emotions, attachment, communication, and self-regulation. New York: W.W. Norton, 2011. [Google Scholar]
- 39. Dames S, Young W, Krigolson O, et al. Changes in cognitive control following a novel resilience-focused nursing educational program: an exploratory study. Qual Adv Nurs Educ 2022; 8(2): 6. [Google Scholar]
- 40. Schwartz T, Trunko ME, Feifel D, et al. A longitudinal case series of IM ketamine for patients with severe and enduring eating disorders and comorbid treatment-resistant depression. Clin Case Rep 2021; 9(5): e03869. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41. Borgland SL, Neyens DM. Serotonergic psychedelic treatment for obesity and eating disorders: potential expectations and caveats for emerging studies. J Psychiatry Neurosci 2022; 47(3): E218–E221. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42. Keeler JL, Treasure J, Juruena MF, et al. Ketamine as a treatment for anorexia nervosa: a narrative review. Nutrients 2021; 13(11): 4158. [DOI] [PMC free article] [PubMed] [Google Scholar]
